Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis
- 331 Downloads
Osteopontin (OPN) is a secreted phosphoprotein, which functions as a cell attachment protein and cytokine that signals through two cell adhesion molecules, integrin αvβ3 and CD44, to regulate cancer growth and metastasis. The aim of this study was to investigate the expression of OPN and integrin αv (ITGAV, main receptor of the OPN) in laryngeal and hypopharyngeal squamous cell carcinoma (LHSCC) and correlate the expression quantity with tumor biological behavior.
We have made a tissue microarray of LHSCC and detected the OPN and ITGAV expression by immunohistochemistry in the microarray. The expression quantity of OPN and ITGAV was determined by a professional pathological image processing software (Image-Pro plus 5.02), and the clinical significances of the expression quantity in LHSCC were analyzed.
The expression quantity of OPN and ITGAV in primary and metastatic carcinomas is significantly higher than in normal tissues. The expression of OPN and ITGAV in the well-differentiated group is significantly lower than in moderately and poorly differentiated group; the expression quantity of OPN and ITGAV in group with lymph node metastasis is significantly higher than in group without lymph node metastasis.
The expression of OPN and ITGAV was significantly influenced to the differentiation and metastasis of the LHSCC. Overexpression of the OPN and ITGAV may have contributed to invasion and metastasis of the LHSCC, and therefore, OPN and ITGAV may have value as a target for chemotherapy in LHSCC treatment.
KeywordsLaryngeal neoplasms Hypopharyngeal neoplasms Osteopontin Integrin αv Differentiation Metastasis
Conflict of interest
- Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M (2005) Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and evasiveness. Clin Cancer Res 11(22):8019–8027PubMedCrossRefGoogle Scholar
- Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T (1999) CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59:219–226PubMedGoogle Scholar
- Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, Rashid MM, Morimoto J, Inobe M, Shijubo N, Chambers AF, Uede T (2002) Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem 84:420–432PubMedCrossRefGoogle Scholar
- Rosai J, Carcangiu ML, DeLellis RA (1992) Atlas of tumor pathology—tumors of the larynx, 3rd series. Armed Force Institute of Pathology, WashingtonGoogle Scholar
- Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Perruzzi CA, Detmar M (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the ß3 integrin, osteopontin, and thrombin. Am J Pathol 149:293–305PubMedGoogle Scholar
- Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D (1999) The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274:36328–36334PubMedCrossRefGoogle Scholar